A statistical method for estimating the no-observed-adverse-event-level

Abstract

In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.

arXiv comment4 data examples, with raw data and R-code

References in corpus (1)

• Closed test procedures for the comparison of dose groups against a negative control group or placebo